Previous 10 | Next 10 |
2023-10-10 10:09:18 ET DENVER, Colo., Oct. 10, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SMX (Security Matters) (NASDAQ: SMX), Immunic (NASDAQ: IMUX), Intrusion (NASDAQ: INTZ), SuperCom (NASDAQ: SPC...
2023-10-10 09:36:15 ET DENVER, Colo., Oct 9, 2023 ( www.247marketnews.com )- Immunic, Inc. (NASDAQ: IMUX) reported, after yesterday’s market close, positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838...
2023-10-09 17:05:57 ET More on Immunic Immunic, Inc. (IMUX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Immunic Financial information for Immunic For further details see: Immunic jumps after the bell on positive interim data fr...
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Mul...
Immunic to Participate in Scientific Conferences in October PR Newswire NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for c...
Immunic to Participate in Industry and Investor Conferences in September PR Newswire NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule t...
(NewsDirect) Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive...
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire – Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 – – Full Data Readout Expected in Ap...
--News Direct-- Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business d...
2023-08-06 01:59:07 ET Immunic, Inc. (IMUX) Q2 2023 Earnings Conference Call August 3, 2023, 08:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants ...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...